Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1Lymphoid 1CNS 1

Conditions

Sarcoma 3Pancreatic Neoplasms 2Liver Neoplasms 2Carcinoma, Hepatocellular 2Uterine Cervical Neoplasms 1Unspecified Adult Solid Tumor, Protocol Specific 1Stomach Neoplasms 1Sarcoma, Synovial 1Rhabdomyosarcoma 1Recurrence 1Prostatic Neoplasms 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Ovarian Neoplasms 1Optic Nerve Glioma 1Oligodendroglioma 1Neurofibrosarcoma 1Neuroectodermal Tumors, Primitive, Peripheral 1Myelodysplastic Syndromes 1Medulloblastoma 1Lymphoma 1Lung Neoplasms 1Liposarcoma 1Leukemia, Myelomonocytic, Chronic 1Leukemia, Myeloid, Acute 1Leukemia, Lymphocytic, Chronic, B-Cell 1Leukemia 1Leiomyosarcoma 1Histiocytoma, Malignant Fibrous 1Hemangiosarcoma 1Hemangiopericytoma, Malignant 1

Interventions

Cyclophosphamide 447Rituximab 406Etoposide 225Vincristine 217Doxorubicin 204Filgrastim 201Prednisone 178Cytarabine 160Radiotherapy 152fludarabine phosphate 148Methotrexate 137Peripheral Blood Stem Cell Transplantation 130Melphalan 128fludarabine 116Busulfan 101Dexamethasone 93Tacrolimus 76Carmustine 74Granulocyte Colony-Stimulating Factor 73Mycophenolic Acid 72Gemcitabine 66Bortezomib 65Antilymphocyte Serum 65Whole-Body Irradiation 63Bendamustine Hydrochloride 63Lenalidomide 62Cyclosporine 62Ifosfamide 58sargramostim 51Methylprednisolone 49

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Lymphoma × exatecan × Clear all
NCT00004212 2012-05-16

DX-8951f in Treating Children With Advanced Solid Tumors or Lymphomas

Daiichi Sankyo

Phase 1 Completed
CNSLymphoidSarcoma

Familial ependymoma, Astrocytoma, Burkitt Lymphoma, Lymphoma, Medulloblastoma, Oligodendroglioma, Recurrence, Central Nervous System Neoplasms, Choroid Plexus Neoplasms, Optic Nerve Glioma, Dendritic Cell Sarcoma, Interdigitating

Data powered by HemOnc (CC BY 4.0) Colophon âš¡